|
|
Vaccine Detail
|
M-M-RVaxPro |
| Vaccine Information |
- Vaccine Name: M-M-RVaxPro
- Target Pathogen: Measles virus
- Target Disease: Measles
- Product Name: Measles and Mumps Virus Vaccine, Live
- Tradename: M-M-RVaxPro
- Manufacturer: Merck and Co., Inc.
- Type: Live, attenuated vaccine
- Status: Licensed
- Location Licensed: USA
- Host Species for Licensed Use: Human
- Allergen: Gelatin, Eggs, Neomycin
- Preparation: A lyophilised preparation of the live Oka strain varicella virus, with a potency of not less than 1350 plaque-forming units. Both vaccines were stored at 2°C to 8°C and reconstituted with sterile water for injections immediately before use. (Gillet et al., 2009)
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Both vaccines were stored at 2°C to 8°C and reconstituted with sterile water for injections immediately before use. (Gillet et al., 2009)
- Approved Age for Licensed Use: 1 year and older
- Description: M-M-RvaxPro is a lyophilised live virus vaccine manufactured with recombinant human albumin for vaccination against measles, mumps and rubella. (Gillet et al., 2009)
|
| Host Response |
|
|
| References |
Gillet et al., 2009: Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC medicine. 2009; 7; 16. [PubMed: 19366435].
|
|
